Abstract
Cannabinoids have potential therapeutic value e.g. in pain relief, cancer therapy, control of nausea and vomiting, and appetite stimulation, but their therapeutic benefits are limited by unwanted central nervous system (CNS) side-effects. Separating the therapeutic effects of cannabinoid agonists from their undesired CNS effects can be achieved by either increasing the selectivity of the ligands for the CB2 receptor or by developing peripherally restricted CB1/CB2 ligands. A vast number of structurally diverse CB2 ligands have been developed during the past 3 years, stemming from the screening hits, which are further optimized towards lead compounds and drug candidates. Some of CB2 ligands may ultimately enter into clinical use as pain relief, anticancer, or antipruritic agents. This review focuses on the recent literature dealing with selective CB2 receptor ligands, with a particular emphasis on the CB2 agonists developed from 2009 onwards.
Keywords: Agonist, anti-proliferative, antipruritics, cannabinoid, CB1, CB2, inverse agonist, pain, partial agonists, peripheral ligands.
Current Medicinal Chemistry
Title:Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands
Volume: 21 Issue: 2
Author(s): Tapio Nevalainen
Affiliation:
Keywords: Agonist, anti-proliferative, antipruritics, cannabinoid, CB1, CB2, inverse agonist, pain, partial agonists, peripheral ligands.
Abstract: Cannabinoids have potential therapeutic value e.g. in pain relief, cancer therapy, control of nausea and vomiting, and appetite stimulation, but their therapeutic benefits are limited by unwanted central nervous system (CNS) side-effects. Separating the therapeutic effects of cannabinoid agonists from their undesired CNS effects can be achieved by either increasing the selectivity of the ligands for the CB2 receptor or by developing peripherally restricted CB1/CB2 ligands. A vast number of structurally diverse CB2 ligands have been developed during the past 3 years, stemming from the screening hits, which are further optimized towards lead compounds and drug candidates. Some of CB2 ligands may ultimately enter into clinical use as pain relief, anticancer, or antipruritic agents. This review focuses on the recent literature dealing with selective CB2 receptor ligands, with a particular emphasis on the CB2 agonists developed from 2009 onwards.
Export Options
About this article
Cite this article as:
Nevalainen Tapio, Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands, Current Medicinal Chemistry 2014; 21 (2) . https://dx.doi.org/10.2174/09298673113206660296
DOI https://dx.doi.org/10.2174/09298673113206660296 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biodistribution and Pharmacokinetics of I-131 Labelled 4- Iodophenylacetic Acid
Current Radiopharmaceuticals Editorial (Thematic Issue: Role of Antioxidants Treatments on Oxidative Stress and Calcium Entry in Neurological Disease: Focus on TRP Channels)
Current Neuropharmacology Searching for Novel Cancer Chemopreventive Plants and their Products:The Genus Zanthoxylum
Current Drug Targets Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry Anti-Cancer Approach with NK4: Bivalent Action and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor
Current Drug Targets Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Current Stem Cell Research & Therapy Big Data to Knowledge: Application of Machine Learning to Predictive Modeling of Therapeutic Response in Cancer
Current Genomics Drugs for AIDS
Mini-Reviews in Medicinal Chemistry Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas
Current Neuropharmacology Synthesis of [<sup>64</sup>Cu]Cu-NOTA-Bn-GE11 for PET Imaging of EGFR-Rich Tumors
Current Radiopharmaceuticals PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Mesenchymal Stem Cells Promote Caspase Expression in Molt-4 Leukemia Cells <i>Via</i> GSK-3α/Β and ERK1/2 Signaling Pathways as a Therapeutic Strategy
Current Gene Therapy Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Design, Synthesis, and Transport Potential of a New Family of Nonionic Amphiphilic Dendro-calix[4]arene
Current Organic Chemistry Senescence and Cell Death Pathways and Their Role in Cancer Therapeutic Outcome
Current Medicinal Chemistry Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets Metabotropic Purinergic Receptors in Lipid Membrane Microdomains
Current Medicinal Chemistry Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design